Novel Oral Derivative UD-017, a Highly Selective CDK7 Inhibitor, Exhibits Anticancer Activity by Inducing Cell-Cycle Arrest and Apoptosis in Human Colorectal Cancer

アクセス数 : 694
ダウンロード数 : 151

今月のアクセス数 : 6
今月のダウンロード数 : 6
ファイル情報(添付)
HiroshimaJMedSci_69_23.pdf 1.06 MB 種類 : 全文
タイトル ( eng )
Novel Oral Derivative UD-017, a Highly Selective CDK7 Inhibitor, Exhibits Anticancer Activity by Inducing Cell-Cycle Arrest and Apoptosis in Human Colorectal Cancer
作成者
Aga Yasuhiro
Matsushita Takashi
Ogi Sayaka
Onuma Kazuhiro
Sunamoto Hidetoshi
Ogawa Ayumi
Kono Shigeyuki
Iwase Noriaki
Tokunaga Yasunori
Ushiyama Shigeru
Nara Futoshi
Konno Yasushi
Yoneda Kenji
収録物名
Hiroshima Journal of Medical Sciences
69
1
開始ページ 23
終了ページ 31
収録物識別子
[PISSN] 0018-2052
[EISSN] 2433-7668
[NCID] AA00664312
抄録
Objective: This study aimed to investigate the anticancer profile of a new cyclin-dependent kinase 7 (CDK7) inhibitor, UD-017, by examining its mechanism of action using HCT-116 colorectal cancer cells.
Methods: The anticancer properties of UD-017 were assessed using several assays, including in vitro kinase, proliferation, and apoptosis assays, western blot analysis, and an in vivo xenograft mouse model.
Results: UD-017 significantly inhibited CDK7 activity (IC50 = 16 nM) with high selectivity in an in vitro kinase assay testing a panel of over 300 proteins and lipid kinases. UD-017 also inhibited the growth of HCT-116 cells (GI50 = 19 nM) and inhibited the phosphorylation of various downstream mediators of CDK7 signaling. In cell cycle and apoptosis assays using HCT-116 cells, UD-017 increased the number of cells in both G1 and G2/M phases and induced apoptosis. In vivo, UD-017 inhibited tumor growth in an HCT-116 xenograft mouse model by 33%, 64%, and 88% at doses of 25, 50, and 100 mg/kg, respectively, with clear dose-dependency. Co-administration of 5-FU and 50 mg/kg UD-017 had a strong synergistic effect, as reflected in the complete inhibition of tumor growth.
Conclusion: CDK7 may play a major role in colorectal cancer growth by regulating the cell cycle and apoptosis. UD-017 is a promising candidate therapeutic agent for the treatment of cancer involving CDK7 signaling.
著者キーワード
UD-017
CDK7 inhibitor
colorectal cancer
HCT-116
言語
英語
資源タイプ 紀要論文
出版者
Hiroshima University Medical Press
発行日 2020-03
権利情報
Copyright (c) 2020 Hiroshima University Medical Press
出版タイプ Version of Record(出版社版。早期公開を含む)
アクセス権 オープンアクセス
収録物識別子
[ISSN] 0018-2052
[ISSN] 2433-7668
[NCID] AA00664312
[DOI] 10.24811/hjms.69.1_23
[DOI] https://doi.org/10.24811/hjms.69.1_23